drugset
drugset / Trial / NCT01330758

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

NCT01330758 ↗

Phase 1 Completed 26 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

A study to compare two different tablet formulations of AZD8931 in healthy males and females.

Timeline

Start
2011-04
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SAPITINIB Small molecule 40 mg —

Indications

No indication recorded.